Growth Metrics

Biogen (BIIB) Common Equity (2016 - 2025)

Biogen has reported Common Equity over the past 17 years, most recently at $18.3 billion for Q4 2025.

  • Quarterly results put Common Equity at $18.3 billion for Q4 2025, up 9.22% from a year ago — trailing twelve months through Dec 2025 was $18.3 billion (up 9.22% YoY), and the annual figure for FY2025 was $18.3 billion, up 9.22%.
  • Common Equity for Q4 2025 was $18.3 billion at Biogen, up from -$171.2 million in the prior quarter.
  • Over the last five years, Common Equity for BIIB hit a ceiling of $18.3 billion in Q4 2025 and a floor of -$171.2 million in Q3 2025.
  • Median Common Equity over the past 5 years was $14.1 billion (2023), compared with a mean of $13.4 billion.
  • Biggest five-year swings in Common Equity: increased 22.87% in 2023 and later plummeted 101.05% in 2025.
  • Biogen's Common Equity stood at $11.0 billion in 2021, then rose by 22.16% to $13.4 billion in 2022, then rose by 10.54% to $14.8 billion in 2023, then increased by 12.95% to $16.7 billion in 2024, then grew by 9.22% to $18.3 billion in 2025.
  • The last three reported values for Common Equity were $18.3 billion (Q4 2025), -$171.2 million (Q3 2025), and $17.6 billion (Q2 2025) per Business Quant data.